On March 24, 2023, MedRx Co., Ltd closed the transaction. The method of capital increase is through third party allotment. The series 25 stock acquisition rights will be exercisable at an initial exercise price of ¥179 per right for 100 shares per stock acquisition right.

The exercise price will be revised for the first time on March 27, 2023, and thereafter, the date on which the exercise request described in paragraph 17 of the issuance guidelines will become effective .